New Test: Antimicrobial Susceptibility Panel, Yeast

Starting **4/25/2018** Laboratory will offer in vitro antifungal susceptibility (MIC) of *Candida* species.

*Candida* species can be one of the leading causes of nosocomial infections and are frequent causes of community-acquired infections.

Antifungal susceptibility testing may aid in the management of patients with invasive infections due to *Candida* species or patients who appear to experiencing therapeutic failure.

The Clinical Laboratory Standards Institute has approved the use of a broth microdilution method for determining the susceptibility of *Candida* species.

This antifungal susceptibility will automatically be performed for appropriate yeast isolates from sterile sites, but can be requested from non-sterile sites with pathology review. This test is validated for *Candida albicans*, *Candida glabrata*, *Candida tropicalis*, *Candida parasilosis* and *Candida krusei*.

This test is not approved for other *Candida* species, *Cryptococcus*, or filamentous molds including dimorphic yeast of filamentous fungi.

**INTERPRETATIVE INFORMATION:**

MIC interpretations are based on recent publications and CLSI guidelines. Species-specific clinical breakpoints are provided as either susceptible (SS), intermediate (I), Susceptible dose Dependent (SDD), or resistant (R). When results are interpreted as susceptible dose-dependent to a specific antifungal agent, it is assumed that maximum blood levels can be achieved.

An additional charge is made for susceptibility testing.

**REFERENCES:**